Recent trends in the Life Sciences industry – increasing fluctuations in demand, the need for new, innovative products, globalization, and significant M&A activity – are adding to the complexity of already intricate supply chains. For example, 2014 was a record year for M&A, with over $200B changing hands.
In addition, with cost pressures on the rise as a result of price erosion, an emphasis on patient outcomes and the patent cliff continuing to face pharmaceutical companies, organizations are limited in the types of investments they can make to impact agility, decrease lead times, and reduce inventory to unlock valuable working capital.
Yet there is no question that the supply chain of the future will require more and more advanced analytics, along with the appropriate simulation and modeling capabilities to evaluate increasingly complex and dynamic risks and constraints and to manage the supply chain more precisely. In addition, the volume of data will continue to grow –sensors on everything from products to machines, the availability of information across business networks – all will need to be incorporated to provide a full picture from which to make supply chain decisions.
So what are the right investments to drive end-to-end visibility for your company? For example, are you making the most of real-time supply chain reporting or are you making decisions from backward looking information? Are you spending time compiling and generating reports from a BW/EDW system or can you quickly analyze relevant planning situations at multiple levels of aggregation?
The focus of this microsession will be the types of analytical supply chain models market leaders are adopting and the results are they seeing. We will also discuss how analytics can drive not only cost efficiencies, but bottom line improvements.
Please stop by to join the discussion, hear from your peers, and lend your insights on Tuesday, May 5th from 3pm – 3:45pm or click on the link below to add this session to your agenda.